Journal of Parkinson's disease最新文献

Winding Back the Clock on Advanced Therapies: It's Time to Get Smart. 让先进疗法的时间倒流：是时候放聪明点了。

IF 5.2 3区医学

Journal of Parkinson's disease Pub Date : 2024-09-06 DOI: 10.3233/jpd-240193

Matthew J Georgiades,Anton A van der Plas,Bastiaan R Bloem,Simon J G Lewis

引用次数: 0

Prospective Study of Lung Function with Prodromal, Clinical Parkinson's Disease, and Mortality. 肺功能与帕金森病前兆、临床和死亡率的前瞻性研究。

IF 5.2 3区医学

Journal of Parkinson's disease Pub Date : 2024-09-06 DOI: 10.3233/jpd-240097

Xiao Chen,Zhicheng Zhang,Lin Tong,Han Wang,Xinming Xu,Liang Sun,Yaqi Li,Xiang Gao

{"title":"Prospective Study of Lung Function with Prodromal, Clinical Parkinson's Disease, and Mortality.","authors":"Xiao Chen,Zhicheng Zhang,Lin Tong,Han Wang,Xinming Xu,Liang Sun,Yaqi Li,Xiang Gao","doi":"10.3233/jpd-240097","DOIUrl":"https://doi.org/10.3233/jpd-240097","url":null,"abstract":"BackgroundThe association of lung function with the risk of developing prodromal and clinical-diagnosed Parkinson's disease (PD) and with the risk of mortality among individuals with PD remains unknown.ObjectiveTo prospectively examine the associations of lung function with the risk of prodromal, clinical-diagnosed PD, and PD-related mortality in participants of the UK Biobank.MethodsIncluded were 452,518 participants free of PD at baseline. Baseline lung function, including forced expiratory volume in 1-s (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF), and FEV1/FVC ratio, was assessed. Eight prodromal features were measured using self-reported diagnoses, hospital admission, and primary care data. Incident PD cases were identified using linkages with hospital admission, death register, and self-report. Vital status and date of death were provided by the UK National Health Service (NHS) and the NHS Central Register. We used Cox proportional hazard models to evaluate these associations.ResultsPoor lung function was associated with higher risk of PD in a dose-response relationship: the adjusted hazard ratio comparing the lowest vs. the highest lung function quintile was 1.18 (95% CI, 1.02- 1.37) for FEV1, 1.14 (95% CI, 0.99- 1.29) for FVC, and 1.23 (95% CI, 1.08- 1.41) for PEF (p-trend <0.05 for all). Similar results were obtained for risk of prodromal PD and mortality among individuals with PD.ConclusionsThe current study showed that individuals with poor lung function had a high future risk of prodromal and clinical PD and a higher rate of PD-related mortality.","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":"55 1","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-Pharmacological Interventions for People with Parkinson's Disease: Are We Entering a New Era? 帕金森病患者的非药物干预：我们是否正在进入一个新时代？

IF 4 3区医学

Journal of Parkinson's disease Pub Date : 2024-06-25 DOI: 10.3233/JPD-249006

E Kalbe, B R Bloem, L V Kalia, A Nieuwboer

引用次数: 0

Prospective Role of PAK6 and 14-3-3γ as Biomarkers for Parkinson’s Disease PAK6 和 14-3-3γ 作为帕金森病生物标记物的前瞻性作用

IF 5.2 3区医学

Journal of Parkinson's disease Pub Date : 2024-04-23 DOI: 10.3233/jpd-230402

Elena Giusto, Lorenza Maistrello, Lucia Iannotta, Veronica Giusti, Ludovica Iovino, Rina Bandopadhyay, Angelo Antonini, Luigi Bubacco, Rita Barresi, Nicoletta Plotegher, Elisa Greggio, Laura Civiero

{"title":"Prospective Role of PAK6 and 14-3-3γ as Biomarkers for Parkinson’s Disease","authors":"Elena Giusto, Lorenza Maistrello, Lucia Iannotta, Veronica Giusti, Ludovica Iovino, Rina Bandopadhyay, Angelo Antonini, Luigi Bubacco, Rita Barresi, Nicoletta Plotegher, Elisa Greggio, Laura Civiero","doi":"10.3233/jpd-230402","DOIUrl":"https://doi.org/10.3233/jpd-230402","url":null,"abstract":"<h4><span>Abstract</span></h4><h3><span></span>Background:</h3><p>\u0000Parkinson’s disease is a progressive neurodegenerative disorder mainly distinguished by sporadic etiology, although a genetic component is also well established. Variants in the <i>LRRK2</i> gene are associated with both familiar and sporadic disease. We have previously shown that PAK6 and 14-3-3γ protein interact with and regulate the activity of LRRK2.</p><h3><span></span>Objective:</h3><p>\u0000The aim of this study is to quantify PAK6 and 14-3-3γ in plasma as reliable biomarkers for the diagnosis of both sporadic and LRRK2-linked Parkinson’s disease.</p><h3><span></span>Methods:</h3><p>\u0000After an initial quantification of PAK6 and 14-3-3γ expression by means of Western blot in post-mortem human brains, we verified the presence of the two proteins in plasma by using quantitative ELISA tests. We analyzed samples obtained from 39 healthy subjects, 40 patients with sporadic Parkinson’s disease, 50 LRRK2-G2019S non-manifesting carriers and 31 patients with LRRK2-G2019S Parkinson’s disease.</p><h3><span></span>Results:</h3><p>\u0000The amount of PAK6 and 14-3-3γ is significantly different in patients with Parkinson’s disease compared to healthy subjects. Moreover, the amount of PAK6 also varies with the presence of the G2019S mutation in the LRRK2 gene. Although the generalized linear models show a low association between the presence of Parkinson’s disease and PAK6, the kinase could be added in a broader panel of biomarkers for the diagnosis of Parkinson’s disease.</p><h3><span></span>Conclusions:</h3><p>\u0000Changes of PAK6 and 14-3-3γ amount in plasma represent a shared readout for patients affected by sporadic and LRRK2-linked Parkinson’s disease. Overall, they can contribute to the establishment of an extended panel of biomarkers for the diagnosis of Parkinson’s disease.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":"29 1","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140806095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neural Oscillations and Functional Significances for Prioritizing Dual-Task Walking in Parkinson’s Disease 帕金森病患者优先考虑双任务行走的神经振荡和功能意义

IF 5.2 3区医学

Journal of Parkinson's disease Pub Date : 2024-03-05 DOI: 10.3233/jpd-230245

Cheng-Ya Huang, Yu-An Chen, Ruey-Meei Wu, Ing-Shiou Hwang

{"title":"Neural Oscillations and Functional Significances for Prioritizing Dual-Task Walking in Parkinson’s Disease","authors":"Cheng-Ya Huang, Yu-An Chen, Ruey-Meei Wu, Ing-Shiou Hwang","doi":"10.3233/jpd-230245","DOIUrl":"https://doi.org/10.3233/jpd-230245","url":null,"abstract":"<h4><span>Abstract</span></h4><h3><span></span>Background:</h3><p>Task prioritization involves allocating brain resources in a dual-task scenario, but the mechanistic details of how prioritization strategies affect dual-task walking performance for Parkinson’s disease (PD) are little understood.</p><h3><span></span>Objective:</h3><p>We investigated the performance benefits and corresponding neural signatures for people with PD during dual-task walking, using gait-prioritization (GP) and manual-prioritization (MP) strategies.</p><h3><span></span>Methods:</h3><p>Participants (N = 34) were asked to hold two inter-locking rings while walking and to prioritize either taking big steps (GP strategy) or separating the two rings (MP strategy). Gait parameters and ring-touch time were measured, and scalp electroencephalograph was performed.</p><h3><span></span>Results:</h3><p>Compared with the MP strategy, the GP strategy yielded faster walking speed and longer step length, whereas ring-touch time did not significantly differ between the two strategies. The MP strategy led to higher alpha (8–12 Hz) power in the posterior cortex and beta (13–35 Hz) power in the left frontal-temporal area, but the GP strategy was associated with stronger network connectivity in the beta band. Changes in walking speed and step length because of prioritization negatively correlated with changes in alpha power. Prioritization-related changes in ring-touch time correlated negatively with changes in beta power but positively with changes in beta network connectivity.</p><h3><span></span>Conclusions:</h3><p>A GP strategy in dual-task walking for PD can enhance walking speed and step length without compromising performance in a secondary manual task. This strategy augments attentional focus and facilitates compensatory reinforcement of inter-regional information exchange.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":"43 1","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140045638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

U.S. Tax Credits to Promote Practical Proactive Preventative Care for Parkinson’s Disease 美国税收抵免促进帕金森病的实用积极预防护理

IF 5.2 3区医学

Journal of Parkinson's disease Pub Date : 2024-03-05 DOI: 10.3233/jpd-240046

Michael S. Okun

{"title":"U.S. Tax Credits to Promote Practical Proactive Preventative Care for Parkinson’s Disease","authors":"Michael S. Okun","doi":"10.3233/jpd-240046","DOIUrl":"https://doi.org/10.3233/jpd-240046","url":null,"abstract":"<h4><span>Abstract</span></h4><p>Persons with Parkinson’s disease (PD) and society at large can profit from a strategic investment into a forward leaning, practical, preventative, and proactive multidisciplinary care policy. The American healthcare system is not easily bent to accommodate this type of care, and thus a tax benefit is an attractive option. An individual federal income tax benefit of $6200 each year for every person residing in the US with a diagnosis of PD, could among other offerings provide monthly access to a licensed clinical social worker and access to mental health services. The implementation of more coordinated care has the potential reduce the burden of depression, anxiety, and demoralization. Personal training would also be covered and directed by physical and occupational therapists. The combination of home-based and telemedicine services would have the added benefit of improving access. The tax benefit would also provide access to a dietician. This type of care strategy could be designed to proactively identify early signs of aspiration and urinary tract infections to ‘head off’ significant morbidity. A $6200/year individual tax benefit for those diagnosed with PD will thus translate into more fall prevention, more care in the home setting, less hospitalizations, less depression, less anxiety, less demoralization, better diets, and less persons placed in nursing facilities. Additionally, this tax benefit will provide the potential for billions of dollars in savings to the healthcare system. A tax benefit for PD is a practical preventative and proactive strategy which can serve to advantage both this generation and the next.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":"301 1","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140045525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dietary Interventions in Parkinson’s Disease 帕金森病的饮食干预

IF 5.2 3区医学

Journal of Parkinson's disease Pub Date : 2024-01-23 DOI: 10.3233/jpd-230366

Indy van der Berg, Sabine Schootemeijer, Karin Overbeek, Bastiaan R. Bloem, Nienke M. de Vries

{"title":"Dietary Interventions in Parkinson’s Disease","authors":"Indy van der Berg, Sabine Schootemeijer, Karin Overbeek, Bastiaan R. Bloem, Nienke M. de Vries","doi":"10.3233/jpd-230366","DOIUrl":"https://doi.org/10.3233/jpd-230366","url":null,"abstract":"<h4><span>Abstract</span></h4><p>Several dietary patterns and nutritional supplements have been linked to the development, progression, and symptomatic treatment of Parkinson’s disease (PD). Most of the evidence, at this point, is preliminary and based largely on observational studies. Interventional studies are scarce, so the evidence on effectiveness remains inconclusive. Dietary interventions could, analogous to exercise, potentially have a beneficial effect on disease symptoms as well as on the progression of the disease and should therefore be researched in high quality studies. Further work is also needed to study whether dietary interventions, when applied to an at-risk population, have any potential to postpone the onset of manifest PD. In this paper, we summarize all ongoing clinical trials on dietary interventions in PD. We found 10 ongoing studies, all aimed at a different intervention. These studies are mostly exploratory in nature or represent phase I or phase II trials focusing on safety, biological responses, and symptomatic effects. Taken together, we conclude that research on dietary interventions in persons with PD is still in its early days. The results of the various ongoing trials are expected to generate new hypotheses and will help to shape the agenda for future research on this important topic.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":"47 1","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139554319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Terminal Care in Parkinson’s Disease: Real-Life Use of Continuous Subcutaneous Apomorphine Infusion to Improve Patient Comfort 帕金森病的临终关怀：持续皮下注射阿扑吗啡改善患者舒适度的实际应用

IF 5.2 3区医学

Journal of Parkinson's disease Pub Date : 2024-01-04 DOI: 10.3233/jpd-230201

Matthieu Béreau, Mathilde Giffard, A. Clairet, Guillaume Degenne, Laurent Tatu, Edward Richfield, Éloi Magnin, M. Vérin, M. Auffret

{"title":"Terminal Care in Parkinson’s Disease: Real-Life Use of Continuous Subcutaneous Apomorphine Infusion to Improve Patient Comfort","authors":"Matthieu Béreau, Mathilde Giffard, A. Clairet, Guillaume Degenne, Laurent Tatu, Edward Richfield, Éloi Magnin, M. Vérin, M. Auffret","doi":"10.3233/jpd-230201","DOIUrl":"https://doi.org/10.3233/jpd-230201","url":null,"abstract":"Background: There are currently no recommendations on the therapeutic management of Parkinson’s disease (PD) patients at the end of life. Objective: To describe a cohort of patients with PD who benefited from continuous subcutaneous apomorphine infusion (CSAI) initiation at the end of their life as comfort care. Methods: This real-life cohort includes 14 PD patients, who benefited from 24-h, low-dose CSAI (0.5–3 mg/h) in the context of terminal care. Patient’s comfort (pain, rigidity, and/or ability to communicate) and occurrence of CSAI-related side-effects (nausea/vomiting, cutaneous and behavioral manifestations) were evaluated based on medical records. Results: All patients (age 62–94 years, disease duration 2–32 years) presented with late-stage PD and a compromised oral route. Treatment lasted from a few hours to 39 days. CSAI led to substantial functional improvement, with a good safety profile. Overall clinical comfort was deemed improved by the medical team, the patient, and/or caregivers. Conclusions: CSAI might be a promising approach in PD terminal care, as it reduces motor symptoms and overall discomfort, with an apparent good safety profile. Use of the apomorphine pen, sublingual film or a classic syringe pump might be considered when apomorphine pumps are not available. Larger observational cohorts and randomized controlled trials are needed to establish the efficacy and tolerability of apomorphine in the context of terminal care and more broadly, in an advance care planning perspective.","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":"34 12","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139450814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Using Extracellular miRNA Signatures to Identify Patients with LRRK2-Related Parkinson's Disease. 利用细胞外 miRNA 标志识别 LRRK2 相关帕金森病患者。

IF 4 3区医学

Journal of Parkinson's disease Pub Date : 2024-01-01 DOI: 10.3233/JPD-230408

Luca Jannik Braunger, Felix Knab, Thomas Gasser

{"title":"Using Extracellular miRNA Signatures to Identify Patients with LRRK2-Related Parkinson's Disease.","authors":"Luca Jannik Braunger, Felix Knab, Thomas Gasser","doi":"10.3233/JPD-230408","DOIUrl":"10.3233/JPD-230408","url":null,"abstract":"<p><strong>Background: </strong>Mutations in the Leucine Rich Repeat Kinase 2 gene are highly relevant in both sporadic and familial cases of Parkinson's disease. Specific therapies are entering clinical trials but patient stratification remains challenging. Dysregulated microRNA expression levels have been proposed as biomarker candidates in sporadic Parkinson's disease.</p><p><strong>Objective: </strong>In this proof-of concept study we evaluate the potential of extracellular miRNA signatures to identify LRRK2-driven molecular patterns in Parkinson's disease.</p><p><strong>Methods: </strong>We measured expression levels of 91 miRNAs via RT-qPCR in ten individuals with sporadic Parkinson's disease, ten LRRK2 mutation carriers and eleven healthy controls using both plasma and cerebrospinal fluid. We compared miRNA signatures using heatmaps and t-tests. Next, we applied group sorting algorithms and tested sensitivity and specificity of their group predictions.</p><p><strong>Results: </strong>miR-29c-3p was differentially expressed between LRRK2 mutation carriers and sporadic cases, with miR-425-5p trending towards significance. Individuals clustered in principal component analysis along mutation status. Group affiliation was predicted with high accuracy in the prediction models (sensitivity up to 89%, specificity up to 70%). miRs-128-3p, 29c-3p, 223-3p, and 424-5p were identified as promising discriminators among all analyses.</p><p><strong>Conclusions: </strong>LRRK2 mutation status impacts the extracellular miRNA signature measured in plasma and separates mutation carriers from sporadic Parkinson's disease patients. Monitoring LRRK2 miRNA signatures could be an interesting approach to test drug efficacy of LRRK2-targeting therapies. In light of small sample size, the suggested approach needs to be validated in larger cohorts.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"977-991"},"PeriodicalIF":4.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11307038/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141288218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-Motor Symptom Management: Insights into Adherence to Treatment Guidelines in Parkinson's Disease Patients. 非运动症状管理：帕金森病患者遵守治疗指南的情况。

IF 5.2 3区医学

Journal of Parkinson's disease Pub Date : 2024-01-01 DOI: 10.3233/JPD-230263

Carin Janz, Jonathan Timpka, Kristina Rosqvist, Gesine Paul, Alexander Storch, Per Odin

{"title":"Non-Motor Symptom Management: Insights into Adherence to Treatment Guidelines in Parkinson's Disease Patients.","authors":"Carin Janz, Jonathan Timpka, Kristina Rosqvist, Gesine Paul, Alexander Storch, Per Odin","doi":"10.3233/JPD-230263","DOIUrl":"10.3233/JPD-230263","url":null,"abstract":"<p><strong>Background: </strong>Non-motor symptoms (NMS) reduce quality of life in Parkinson's disease (PD) patients, who experience three times more NMS than individuals without PD. While there are international and national NMS treatment guidelines, their implication in clinical practice remains unclear.</p><p><strong>Objective: </strong>This study aimed to investigate the adherence to pharmacological NMS treatment guidelines in patients with mild to moderately severe PD.</p><p><strong>Methods: </strong>220 PD patients with ≥1 NMS based on the Non-Motor Symptom Questionnaire and a Hoehn and Yahr stage ≤4 were randomly selected from the Swedish Parkinson registry and screened for inclusion. NMS were evaluated using the International Parkinson and Movement Disorder Society-Non-Motor Rating Scale (MDS-NMS), Parkinson's Disease Sleep Scale 2, Epworth Sleepiness Scale, and Hospital Anxiety and Depression Scale. Treatment was compared with Swedish national guidelines and international guidelines from the MDS Evidence-Based Medicine Committee.</p><p><strong>Results: </strong>Among 165 included patients, the median number of NMS was 14, and in median 7 symptoms were estimated to require treatment. The most common NMS requiring treatment were pain (69%) and urinary problems (56%). Treatment of depression and constipation demonstrated the highest adherence to guidelines (79% and 77%), while dysphagia and excessive daytime sleepiness exhibited the lowest adherence (0% and 4%). On average, only 32% of NMS were treated in accordance with guidelines.</p><p><strong>Conclusions: </strong>Adherence to pharmacological guidelines for NMS in patients with mild to severe PD was low. This study highlights the need for improved evaluation and treatment of NMS to enhance symptom management and quality of life among PD patients.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"297-312"},"PeriodicalIF":5.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10977407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0